Ticlopidine (Ticlid)

Ticlopidine is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis.

Also Known As:

Networked: 1017 relevant articles (102 outcomes, 144 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Matsumoto, Masayasu: 4 articles (07/2014 - 09/2005)
2.	Uchiyama, Shinichiro: 4 articles (07/2013 - 09/2003)
3.	Bennett, Charles L: 4 articles (06/2013 - 02/2009)
4.	Raife, Thomas J: 4 articles (06/2013 - 01/2004)
5.	Shinohara, Yukito: 4 articles (05/2012 - 04/2003)
6.	Winters, Jeffrey L: 3 articles (06/2013 - 02/2009)
7.	Ortel, Thomas L: 3 articles (06/2013 - 02/2009)
8.	Kwaan, Hau C: 3 articles (06/2013 - 02/2009)
9.	McKoy, June M: 3 articles (06/2013 - 02/2009)
10.	Zheng, X Long: 3 articles (06/2013 - 02/2009)

Related Diseases

1.	Stroke (Strokes) 03/01/1996 - "Thus, ticlopidine is effective in reducing the risk of recurrent cerebral ischaemia and stroke. " 10/01/1993 - "Ticlopidine may also be effective in reducing the risk of recurrent stroke in patients who have had a completed thromboembolic stroke." 10/01/1993 - "Two large, multicenter trials have shown that ticlopidine is effective in reducing the risk of fatal and nonfatal stroke in both men and women. " 06/01/1992 - "Ticlopidine is effective for both primary and secondary stroke prevention. " 01/01/2009 - "Few studies examined the role of ticlopidin in acute stroke setting the results showed treatment with ticlopidine improved the neurologic outcome. "
2.	Thrombosis (Thrombus) 03/01/1993 - "Since shear-induced platelet aggregation can cause thrombotic occlusions in stenotic arterial vessels, our findings may explain the therapeutic efficacy of ticlopidine in arterial thrombosis." 01/01/1983 - "Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications." 01/01/2006 - "In j-Cypher trial, a observational registry trial in Japan, revealed that the subacute thrombosis rate was lower level of the other studies and safety of DES utilization with ticlopidine based antiplatelet regimen. " 07/01/2010 - "By multivariate analysis, HHD (p<0.01), ticlopidine (p=0.01), and CRP (p=0.03) were independently associated with LA thrombus. " 05/01/2007 - "These late thromboses occurred about 2 years after SES implantation and over 1.5 years after discontinuation of ticlopidine."
3.	Myocardial Infarction 01/01/2012 - "This trial compared ticlopidine to placebo and did not demonstrate any statistically significant differences for all-cause mortality, vascular mortality or myocardial infarction. " 04/01/2003 - "A 52-year-old man with acute myocardial infarction developed respiratory distress 2 days after receiving ticlopidine for coronary artery stenting. " 10/01/1999 - "A 54-year-old man had been treated with Ticlopidine for antithrombotic therapy after a myocardial infarction. " 11/01/1998 - "The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions." 12/01/1991 - "Nevertheless, this report strongly suggests that such patients can benefit from antiplatelet treatment with ticlopidine; the benefit mainly depends on the protective effect against myocardial infarction."
4.	Hemorrhage 05/01/2002 - "Gastrointestinal side effects, including bleeding, have been reported with use of ticlopidine in most of the vascular prevention trials. " 04/01/2012 - "The system organ classes with significant disproportionality for ticlopidine included White Cell Disorders (ROR=22.43, 95% CI 18.54-27.12), Red Cell Disorders (8.22; 6.03-11.18), Liver And Biliary System (6.67; 5.35-8.32), Platelet, Bleeding & Clotting (6.59; 5.16-8.40). " 11/01/1998 - "Nevertheless, hemorrhage continues to be a problem with ticlopidine therapy." 09/01/1994 - "Ticlopidine, bleeding, and surgery." 11/01/1993 - "Ticlopidine was tolerated better and no bleeding complications were recorded. "
5.	Neutropenia 06/01/1997 - "Despite the potential benefits of therapy with ticlopidine observed in these studies, hematologic monitoring is required to detect neutropenia that may occur during ticlopidine therapy. " 01/01/2009 - "Authors describe a case of neutropenia induced by ticlopidine. " 01/01/2009 - "[Neutropenia induced by ticlopidine: a delayed onset case]." 07/01/2002 - "[Severe neutropenia induced by ticlopidine. " 07/01/2001 - "The patient evolved with neutropenia induced by ticlopidine after 10 days of treatment. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	clopidogrel (Plavix)
3.	Dipyridamole (Persantine)
4.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
5.	Heparin (Liquaemin)
6.	Warfarin (Coumadin)
7.	cilostazol (Pletal)
8.	Ticlopidine (Ticlid)
9.	thienopyridine
10.	triflusal

Related Therapies and Procedures

1.	Stents
2.	Angioplasty (Angioplasty, Transluminal)
3.	Transplants (Transplant)
4.	Renal Dialysis (Hemodialysis)
5.	Aftercare (After-Treatment)